Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Launched by UNIVERSITY OF TENNESSEE · Sep 25, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at how a treatment called Y90 radioembolization affects patients with liver cancer, specifically hepatocellular carcinoma (HCC). The study aims to understand how much radiation patients are exposed to during the treatment and how well the Y90 microspheres are delivered to the liver. This is important for ensuring the treatment is safe and effective.

To participate in this study, patients need to be undergoing Y90 radioembolization therapy using specific products called SIR-Spheres or TheraSpheres. They must also be able to handle some extra imaging tests and blood draws before, during, and after the treatment. However, patients who are not suitable for the Y90 therapy or who cannot manage these additional procedures will not be included. If you join the trial, you can expect to undergo these extra tests to help researchers gather important information about the treatment's effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
• • Must be able to schedule and tolerate additional PET/CT imaging following therapy
• • Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.
• Exclusion Criteria:
• • Patients that are not candidates for Y90 radioembolization therapy
• • Patients that cannot tolerate additional imaging procedures following therapy
• • Patients that cannot tolerate the additional blood draws required for this study
• • Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study